Skip to contentL
Lyell Immunopharma, Inc.
L
LYELLyell Immunopharma, Inc. Q3 2023 · 10-Q
Revenue$25.00K$25.00K+733.3% vs Q3 2022 Net Income-$50.85M-$50.85MN/M vs Q3 2022 EPS Diluted-$0.20-$0.20N/M vs Q3 2022 Operating Income-$59,039,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lyell Immunopharma, Inc. · CIK 1806952 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$37,881,000N/M Margins · derivedOperating margin-236156.0%+1978410.7 pt vs Q3 2022
Net margin-203412.0%+2138388.0 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 7, 2023 · 38 d after period end